Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.
about
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis.The effect of SGLT2 inhibitors on cardiovascular events and renal function.Review article: new treatments in non-alcoholic fatty liver disease.Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice.Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization.Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
P2860
Q35957448-D93652F9-0896-4F7A-AE69-EA511F22D581Q36532294-5591BCAA-6F04-436A-8D7A-E85EE4758A12Q38614488-5D7D13F9-0699-401D-8396-E9B83AC5483FQ38662765-63E9FCBD-6200-4796-9B9D-1D257EE6A0E0Q38674014-409482A7-4F47-4C94-BC51-474ECCE61A80Q38778064-8E0B03B3-011F-47B8-88BC-FCA036338E37Q39124526-6FADB3EA-97D8-4991-9866-D0BC7D9B2629Q40106543-04B9E87A-73A2-4E9B-8C1E-04D53635F669Q41084455-87627E8E-A4FD-4994-B5DF-B47EA0A2714EQ41623607-32F27915-E90A-40AC-B33E-1260F8B38177Q41709525-AD33B5B6-861C-4023-ACA0-3806FDAEE5D6Q42404578-EFFA839E-5B8D-4929-B604-2E2DB6AD5321Q43266021-37267AD2-58E9-4854-AD20-B9D6B950BCF8Q46320593-35660D1F-56F9-4BCF-B319-E4470655A1D7Q48103374-104C4584-BD56-4FA6-8C85-6701D1632912Q49617047-E08C8ABA-8670-4F5D-9C9E-B645E9F9E7E7Q58564836-CFFD6E82-F43C-46FA-9767-A7A88A7674F5
P2860
Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Treatment with the SGLT2 inhib ...... model with diabetes mellitus.
@en
Treatment with the SGLT2 inhib ...... model with diabetes mellitus.
@nl
type
label
Treatment with the SGLT2 inhib ...... model with diabetes mellitus.
@en
Treatment with the SGLT2 inhib ...... model with diabetes mellitus.
@nl
prefLabel
Treatment with the SGLT2 inhib ...... model with diabetes mellitus.
@en
Treatment with the SGLT2 inhib ...... model with diabetes mellitus.
@nl
P2093
P2860
P1476
Treatment with the SGLT2 inhib ...... model with diabetes mellitus.
@en
P2093
Hideaki Kamata
Hideyuki Sakoda
Keiichi Mori
Midori Fujishiro
Shirong Qiang
Takeshi Yamamotoya
Tomoichiro Asano
Yasuka Matsunaga
Yasuyuki Seno
Yusuke Nakatsu
P2860
P2888
P356
10.1186/S13098-015-0102-8
P577
2015-11-19T00:00:00Z
P5875
P6179
1010358022